Regeneron. 1) does your ED give it, 2) if so does your hospital have any?

[Jabbed]

I mean an NNT of 30 is actually good. The NNT for ASA in ACS is ~50. The issue is more weak data and indication creep. The positive outcome only comes from a subgroup analysis that is likely not replicatable and we are now applying it uniformly to all populations.

Plus it makes me feel dirty.

---

Members don't see this ad.

 

[Jabbed]

BAM is decent against Delta. It sucks against gamma which the CDC might be a thing in the spring. We give it because we give what the government lets us have.

Any data? The last RCTs that I saw on bamlanivimab were all uniformly negative. I never saw anything specific on delta variant aside from in vitro studies.

 

[Dr Mantis Toboggan]

Regen article is out!

https://www.nejm.org/doi/full/10.1056/NEJMoa2108163?query=featured_home

NNT for the 2400 mg dose appears to be 30 to prevent a death or admission if my calculations are correct…

 

[turkeyjerky]

Must be noted that this was in the pre-vaccine era.

 

[Cinclus]

I was notified a few days ago that we are now out of it.

 

[GeneralVeers]

At $2100 per dose, an NNT of 30 seems terrible. Basically spending $60k, to prevent one hospital admission? Seems like the only party making good on that deal is the drug company.

 

[southerndoc]

A lot cheaper than many of the drugs with use that have higher NNT's.

 

[Jabbed]

5000+ patients enrolled and only 5 deaths. 3 were in placebo group and 2 in regeneron, so unlikely to be of statistical difference.

The "combined endpoint of hospitalization and death" is essentially just hospitalization. Overall hospitalization rate in placebo group is 4.6% vs 1.3% in regeneron group. So overall a 3.3% absolute risk reduction.

There's no mention of the severity of illness among hospitalized patients, but given that there were only 5 fatalities I find it unlikely that many were intubated.

Each infusion costs $1250. With an NNT of 30 it costs $37,500 to prevent one covid-19 related hospitalization. There is no mortality benefit.

 

[southerndoc]

5000+ patients enrolled and only 5 deaths. 3 were in placebo group and 2 in regeneron, so unlikely to be of statistical difference.

The "combined endpoint of hospitalization and death" is essentially just hospitalization. Overall hospitalization rate in placebo group is 4.6% vs 1.3% in regeneron group. So overall a 3.3% absolute risk reduction.

There's no mention of the severity of illness among hospitalized patients, but given that there were only 5 fatalities I find it unlikely that many were intubated.

Each infusion costs $1250. With an NNT of 30 it costs $37,500 to prevent one covid-19 related hospitalization. There is no mortality benefit.

I would say that's worth it. Plus factor in the cost of society's lost work potential.

 

[Siggy]

At $2100 per dose, an NNT of 30 seems terrible. Basically spending $60k, to prevent one hospital admission? Seems like the only party making good on that deal is the drug company.

Does anyone know what the NNT and cost for the vaccines are?

 

[GeneralVeers]

Does anyone know what the NNT and cost for the vaccines are?

Billions and Billions to the drug companies.

 

[miacomet]

Yes. Yes.
They discourage vaccination and promote Regeneron because $$$.